BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 27023690)

  • 1. Assessment of the Level of Satisfaction and Unmet Data Needs for Specialty Drug Formulary Decisions in the United States.
    Choi Y; Navarro RP
    J Manag Care Spec Pharm; 2016 Apr; 22(4):368-75. PubMed ID: 27023690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance-Based Risk-Sharing Arrangements: U.S. Payer Experience.
    Goble JA; Ung B; van Boemmel-Wegmann S; Navarro RP; Parece A
    J Manag Care Spec Pharm; 2017 Oct; 23(10):1042-1052. PubMed ID: 28944728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Payer perceptions of the use of real-world evidence in oncology-based decision making.
    Brixner D; Biskupiak J; Oderda G; Burgoyne D; Malone DC; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Aug; 27(8):1096-1105. PubMed ID: 34337998
    [No Abstract]   [Full Text] [Related]  

  • 4. Opinions regarding the Academy of Managed Care Pharmacy dossier submission guidelines: results of a small survey of managed care organizations and pharmaceutical manufacturers.
    Nichol MB; Knight TK; Epstein J; Honda DH; Tretiak R
    J Manag Care Pharm; 2007 May; 13(4):360-71. PubMed ID: 17506602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Schizophrenia population health management: perspectives of and lessons learned from population health decision makers.
    Roach M; Lin D; Graf M; Pednekar P; Chou JW; Benson C; Doshi JA
    J Manag Care Spec Pharm; 2021 Oct; 27(10-a Suppl):S2-S13. PubMed ID: 34652218
    [No Abstract]   [Full Text] [Related]  

  • 7. Payer perceptions on the use of economic models in oncology decision making.
    Biskupiak J; Oderda G; Brixner D; Burgoyne D; Arondekar B; Niyazov A
    J Manag Care Spec Pharm; 2021 Nov; 27(11):1560-1567. PubMed ID: 34714111
    [No Abstract]   [Full Text] [Related]  

  • 8. AMCP Partnership Forum: Enabling the Exchange of Clinical and Economic Information Pre-FDA Approval.
    J Manag Care Spec Pharm; 2017 Jan; 23(1):105-112. PubMed ID: 28025919
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of economic analyses in U.S. managed care formulary decisions: a private payer's experience.
    Watkins JB; Minshall ME; Sullivan SD
    J Manag Care Pharm; 2006; 12(9):726-35. PubMed ID: 17249905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulary management in the Department of Defense.
    Trice S; Devine J; Mistry H; Moore E; Linton A
    J Manag Care Pharm; 2009 Mar; 15(2):133-46. PubMed ID: 19236127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK; Sause RB; Zacker C
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Effect of Formulary Restrictions on Patient and Payer Outcomes: A Systematic Literature Review.
    Park Y; Raza S; George A; Agrawal R; Ko J
    J Manag Care Spec Pharm; 2017 Aug; 23(8):893-901. PubMed ID: 28737993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physicians' opinions about responsibility for patient out-of-pocket costs and formulary prescribing in two Midwestern states.
    Khan S; Sylvester R; Scott D; Pitts B
    J Manag Care Pharm; 2008 Oct; 14(8):780-9. PubMed ID: 18983207
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using a Budget Impact Model Framework to Evaluate Antidiabetic Formulary Changes and Utilization Management Tools.
    Hung A; Mullins CD; Slejko JF; Haines ST; Shaya F; Lugo A
    J Manag Care Spec Pharm; 2019 Mar; 25(3):342-349. PubMed ID: 30816818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical technology assessment: perspectives from payers.
    Leung MY; Halpern MT; West ND
    J Manag Care Pharm; 2012 Apr; 18(3):256-64. PubMed ID: 22468734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the Presence of Cognitive Biases in Health Care Decision Making: A Survey of U.S. Formulary Decision Makers.
    Mezzio DJ; Nguyen VB; Kiselica A; O'Day K
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1173-1183. PubMed ID: 30362919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMCP Partnership Forum: FDAMA Section 114-Improving the Exchange of Health Care Economic Data.
    J Manag Care Spec Pharm; 2016 Jul; 22(7):826-31. PubMed ID: 27333323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the Training, Responsibilities, and Practices of P&T Committee Members and Nonmember Contributors.
    Rodriguez R; Kelly BJ; Moody M
    J Manag Care Spec Pharm; 2017 Aug; 23(8):868-874. PubMed ID: 28737984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Approaches to the management of agents used for the treatment of multiple sclerosis: consensus statements from a panel of U.S. managed care pharmacists and physicians.
    Miller RM; Happe LE; Meyer KL; Spear RJ
    J Manag Care Pharm; 2012; 18(1):54-62. PubMed ID: 22235955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.